TABLE 2.
Demographics and characteristics of patients.
| Characteristics | Total (n = 145) | Before PSM | After PSM | ||
|---|---|---|---|---|---|
| NSGLT2i (n = 69) | SGLT2i (n = 76) | NSGLT2i (n = 47) | SGLT2i (n = 47) | ||
| Patients’ characteristics | |||||
| Age (year) | 54.3 ± 1.2 | 54.9 ± 1.8 | 53.7 ± 1.6 | 56.0 ± 2.1 | 55.6 ± 2.1 |
| Male | 106 (73.1) | 46 (66.7) | 60 (78.9) | 31 (66.0) | 36 (76.6) |
| Body weight (kg) | 73.2 ± 1.3 | 68.1 ± 1.8 | 78.0 ± 1.8** | 71.1 ± 2.2 | 74.8 ± 2.2 |
| Body mass index | 25.3 ± 0.4 | 24.2 ± 0.5 | 26.3 ± 0.4** | 25.2 ± 0.7 | 25.4 ± 0.5 |
| Combined disease and risks | |||||
| Overall (n) | 7.6 ± 0.3 | 7.6 ± 0.4 | 7.5 ± 0.3 | 8.0 ± 0.4 | 7.3 ± 0.4 |
| Hypertension | 71 (49.0) | 32 (46.4) | 39 (51.3) | 25 (53.2) | 25 (53.2) |
| Coronary heart disease | 15 (10.3) | 6 (8.7) | 9 (11.8) | 5 (10.6) | 4 (8.5) |
| Chronic kidney disease | 12 (8.3) | 6 (8.7) | 6 (7.9) | 5 (10.6) | 4 (8.5) |
| Hyperlipemia | 68 (46.9) | 27 (39.1) | 41 (53.9) | 18 (38.3) | 25 (53.2) |
| eGFR | 99.4 ± 1.8 | 99.6 ± 2.6 | 99.3 ± 2.4 | 97.8 ± 3.5 | 97.6 ± 3.2 |
| Diabetes related indicators | |||||
| Diabetic duration (year) | 8.6 ± 0.7 | 9.5 ± 1.1 | 7.9 ± 0.9 | 10.3 ± 1.3 | 8.0 ± 1.1 |
| HbA1c% | 9.7 ± 0.2 | 9.6 ± 0.3 | 9.9 ± 0.3 | 9.8 ± 0.4 | 9.6 ± 0.3 |
| FPG (mmol/L) | 7.6 ± 0.2 | 7.1 ± 0.3 | 7.9 ± 0.3 | 7.4 ± 0.3 | 7.2 ± 0.3 |
| PPG (mmol/L) | 14.3 ± 0.4 | 14.5 ± 0.6 | 14.1 ± 0.5 | 14.1 ± 0.7 | 14.5 ± 0.6 |
| Combined drugs use | |||||
| Overall (n) | 6.0 ± 0.2 | 5.7 ± 0.3 | 6.2 ± 0.3 | 6.4 ± 0.3 | 5.9 ± 0.3 |
| Antihypertensive drugs | 51 (35.2) | 26 (37.7) | 25 (32.9) | 20 (42.6) | 16 (34.0) |
| Lipid-lowering drugs | 103 (71.0) | 47 (68.1) | 56 (73.7) | 30 (63.8) | 30 (63.8) |
| Antiplatelet drug | 41 (28.3) | 15 (21.7) | 26 (34.2) | 12 (25.5) | 16 (34.0) |
| UA lowering drugs | 31 (21.4) | 11 (15.9) | 20 (26.3) | 8 (17.0) | 11 (23.4) |
| Anti-diabetic drugs use | |||||
| Overall (n) | 2.8 ± 0.1 | 2.5 ± 0.1 | 3.1 ± 0.1** | 2.9 ± 0.1 | 2.9 ± 0.1 |
| Metformin | 107 (73.8) | 45 (65.2) | 62 (81.6)* | 37 (78.7) | 34 (72.3) |
| α glycosidase inhibitor | 75 (51.7) | 37 (53.6) | 38 (50.0) | 31 (66.0) | 21 (44.7)* |
| Sulfonylureas | 19 (13.1) | 10 (14.5) | 9 (11.8) | 8 (17.0) | 2 (4.3)* |
| non-Sulfonylurea | 8 (5.5) | 5 (7.2) | 3 (3.9) | 5 (10.6) | 3 (6.4) |
| DPP4i | 48 (33.1) | 31 (44.9) | 17 (22.4)** | 24 (51.1) | 11 (23.4)** |
| GLP-1 RAs | 20 (13.8) | 9 (13.0) | 11 (14.5) | 9 (19.2) | 4 (8.5) |
| SGLT2i | 76 (52.4) | - | 76 (100) | - | 47 (100) |
| Insulin | 50 (34.5) | 31 (44.9) | 19 (25.0)** | 18 (38.3) | 12 (25.5) |
Results were presented with mean ± SE., Abbreviations; PSM, propensity score matching, SGLT2i, sodium-glucose co-transporter 2 inhibitors, NSGLT2i, non- SGLT2i, DPP4i, dipeptidyl peptidase IV, inhibitors; GLP-1, ras, Glucagon like peptide-1 receptor agonists. *p < 0.05 and **p < 0.01 when compared to NSGLT2i group.